Press releases - Vicore Pharma

2025-06-30 | Regulatory

Increase in number of shares and votes in Vicore Pharma

2025-05-28

Vicore to Present at the Jefferies Global Healthcare Conference

2025-05-22

Vicore Presents New Data at the 2025 American Thoracic Society International Conference

2025-05-06 | Regulatory

Bulletin from the annual general meeting of Vicore Pharma Holding AB (publ)

2025-05-06 | Regulatory

Interim Report January – March 2025

2025-05-02

Vicore to Present at the Nordea Equities Healthcare Seminar

2025-04-23

Vicore Announces Presentations at the 2025 American Thoracic Society International Conference

2025-03-28

Vicore to Participate in the Van Lanschot Kempen Life Sciences Conference

2025-03-26 | Regulatory

Notice of Annual General Meeting of Vicore Pharma Holding AB (publ)

2025-03-26 | Regulatory

Vicore publishes the Annual Report for 2024

2025-02-27 | Regulatory

Year-end report 2024

2025-02-26

Vicore to Present at Upcoming Investor Conferences

2025-02-10

Vicore to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference

2025-01-29

The FDA Grants Vicore’s Buloxibutid Fast Track Designation for Idiopathic Pulmonary Fibrosis

2024-11-14

Vicore to Present at Upcoming Investor Conferences

2024-11-05 | Regulatory

Interim report July-September 2024

2024-11-04 | Regulatory

Vicore announces the Nomination Committee for the 2025 Annual General Meeting

2024-10-31 | Regulatory

Increase in number of shares and votes in Vicore Pharma

2024-10-07 | Regulatory

Vicore Pharma has successfully carried out a directed share issue of approximately SEK 100 million

2024-10-07

Vicore Pharma raises approximately SEK 782 million through an oversubscribed rights issue

2024-10-04 | Regulatory

Vicore Pharma publishes preliminary outcome in the rights issue

2024-09-30

Vicore Announces Investment from Sanofi

2024-09-18

Vicore Publishes Prospectus Relating to the Rights Issue

2024-09-17

Vicore Announces Additional Subscription Undertaking from HealthCap

2024-09-10 | Regulatory

Vicore Pharma announces a rights issue of approximately SEK 782 million

2024-09-10

Vicore Initiates the Global, Randomized Phase 2b ASPIRE Trial Evaluating the Disease-Modifying Potential of Buloxibutid in Idiopathic Pulmonary Fibrosis

2024-08-29

Vicore Announces Presentations at the European Respiratory Society Congress 2024

2024-08-22 | Regulatory

Interim report April-June 2024

2024-05-31 | Regulatory

Increase of number of shares and votes in Vicore Pharma

2024-05-20

Vicore Announces Positive Final Results from the Phase 2a AIR Trial Demonstrating Buloxibutid Improves Lung Function Over 36 Weeks in Patients with Idiopathic Pulmonary Fibrosis

2024-05-14

Vicore Expands and Strengthens its Board of Directors

2024-05-07 | Regulatory

Bulletin from the annual general meeting of Vicore Pharma Holding AB (publ)

2024-05-03 | Regulatory

Interim report January-March 2024

2024-04-12

Vicore to Present at Upcoming Investor Conferences

2024-04-04 | Regulatory

Notice of annual general meeting of Vicore Pharma Holding AB (publ)

2024-03-28

Vicore Announces Presentations at the 2024 American Thoracic Society International Conference

2024-03-27 | Regulatory

Vicore publishes the Annual Report for 2023

2024-03-19

Vicore Announces FDA Breakthrough Device Designation for AlmeeTM, a Digital Therapy for Patients with Pulmonary Fibrosis

2024-02-28 | Regulatory

Year-end report 2023

2024-02-27

Vicore to Present at Upcoming Investor Conferences

2024-02-09 | Regulatory

Vicore and Nippon Shinyaku Enter into an Exclusive License Agreement to Develop and Commercialize C21 in Japan

2024-01-31

Vicore to Present at Upcoming Investor Conferences

2024-01-04

Vicore Reports Positive Results for the Pivotal Study of its Digital Therapy for Patients with Pulmonary Fibrosis

2024-01-02

Vicore Confirms IPF Development Program on Track and Provides Early-Stage Pipeline Updates

2023-12-18

Vicore Appoints Leading Respiratory Medicine Developer Dr. Bertil Lindmark MD, PhD, as Chief Medical Officer

2023-12-11

Vicore to Present at the 2023 DNB Nordic Healthcare Conference

2023-11-15

Vicore to Present at 2023 SEB Healthcare Seminar

2023-11-07

Vicore to Present at the Stifel 2023 Healthcare Conference

2023-11-02 | Regulatory

Interim report July-September 2023

2023-10-31 | Regulatory

Vicore announces the Nomination Committee for the 2024 Annual General Meeting

2023-10-27

Vicore provides update regarding Phase 1 study of C106

2023-09-08

Ahmed Mousa starts as the new CEO of Vicore tomorrow

2023-09-06

Vicore Pharma Announces Presentations at the European Respiratory Society (ERS) International Congress 2023

2023-09-01

Vicore Pharma Announces Presentation at the Pareto Securities 14th Annual Healthcare Conference

2023-08-24 | Regulatory

Interim report April-June 2023

2023-08-22

Vicore reports data from EndoPAT® exploratory trial

2023-07-31 | Regulatory

Increase of number of shares and votes in Vicore Pharma

2023-07-13 | Regulatory

Vicore announces the appointment of Ahmed Mousa as CEO

2023-07-07 | Regulatory

Vicore Pharma publishes a prospectus for admission to trading of shares on Nasdaq Stockholm

2023-07-05 | Regulatory

Vicore announces CEO recruitment process

2023-07-05 | Regulatory

Bulletin from the extraordinary general meeting of Vicore Pharma Holding AB (publ)

2023-06-30 | Regulatory

Increase of number of shares and votes in Vicore Pharma

2023-06-09 | Regulatory

Notice of extraordinary general meeting of Vicore Pharma Holding AB (publ)

2023-06-09 | Regulatory

Vicore has carried out directed share issuances of in total 29,875,000 shares at a subscription price of SEK 16.75 per share, raising gross proceeds of SEK 500 million

2023-06-08 | Regulatory

Vicore intends to carry out directed share issuances

2023-06-07

Vicore further strengthens patent protection for C21

2023-05-23

Vicore obtains significant new patent protection for C21 in the US

2023-05-19

Vicore reports new 36-week data from the AIR trial demonstrating sustained disease stabilization and increase in lung function in IPF patients

2023-05-17

Vicore to host webcast with updated AIR trial results after presentation at the ATS congress

2023-05-12

Vicore strengthens its Board of Directors

2023-05-11 | Regulatory

Bulletin from the annual general meeting of Vicore Pharma Holding AB (publ)

2023-05-04 | Regulatory

Correction: Interim report January-March 2023

2023-05-04 | Regulatory

Interim report January-March 2023

2023-05-03

Vicore initiates clinical proof-of-concept study of endothelial dysfunction

2023-04-05 | Regulatory

Notice of annual general meeting of Vicore Pharma Holding AB (publ)

2023-04-05 | Regulatory

Vicore Pharma publishes the Annual Report for 2022

2023-03-31

Vicore to announce AIR trial update at the ATS congress on May 21st

2023-03-29

Vicore receives Innovation Passport designation by the UK regulatory agency MHRA for C21 in IPF

2023-02-28 | Regulatory

Year-end report 2022

2022-12-30 | Regulatory

Increase of number of shares and votes in Vicore Pharma

2022-12-08 | Regulatory

Vicore has carried out a directed share issue of 10,000,000 shares at a subscription price of SEK 20 per share, raising gross proceeds of SEK 200 million

2022-12-07 | Regulatory

Vicore intends to carry out a directed share issue

2022-12-05

Vicore announces first patient enrolled in COMPANION; a digital therapeutic pivotal study for patients with pulmonary fibrosis

2022-11-03 | Regulatory

Vicore announces new data from the IPF AIR trial further strengthening the benefit-risk profile of C21

2022-11-03 | Regulatory

Interim report July-September 2022

2022-10-20 | Regulatory

Vicore announces the Nomination Committee for the 2023 Annual General Meeting

2022-10-12

Vicore selects new ATRAG as next Drug Candidate

2022-10-06

Vicore’s digital therapeutic for IPF patients shows nearly 50% anxiety reduction in pilot study

2022-09-22

Vicore announces that C21 promotes vascular function in humans

2022-09-15 | Regulatory

Vicore provides an update on the ATTRACT-3 COVID-19 trial

2022-09-02

Vicore update on the AIR phase 2 trial in idiopathic pulmonary fibrosis

2022-08-25 | Regulatory

Interim report April – June 2022

2022-08-19

Vicore announces multiple scientific abstracts and presentations at upcoming conferences during the autumn

2022-08-17

Vicore IPF interim data selected as an oral “late-breaker” at the ERS congress

2022-06-30 | Regulatory

Increase of number of shares and votes in Vicore Pharma

2022-06-17

Vicore resolves on a set-off issue of 87,686 shares as part of milestone compensation

2022-06-16

Vicore announces first human dosed with novel ATRAG, C106

2022-06-03

Vicore amends primary endpoint to accelerate the Phase 3 trial in COVID-19 patients

2022-05-11 | Regulatory

Bulletin from the annual general meeting of Vicore Pharma Holding AB (publ)

2022-05-05 | Regulatory

Interim report January – March 2022

2022-04-21

Vicore launches COMPANION, a clinical study investigating the benefit of digital therapy on anxiety in patients with idiopathic pulmonary fibrosis (IPF)

2022-04-07 | Regulatory

Notice of annual general meeting of Vicore Pharma Holding AB (publ)

2022-04-07 | Regulatory

Vicore Pharma publishes the Annual Report for 2021

2022-03-23

Michael Wolff Jensen resigns from the Vicore board of directors and is replaced by Jacob Gunterberg as chairman of the board up until the annual general meeting in May 2022

2022-03-18

Vicore initiates human forearm blood flow study with C21

2022-03-09

Vicore strengthens rare lung disease pipeline with PAH indication

2022-03-04

Vicore to host R&D Day

2022-02-25 | Regulatory

Year-end report 2021

2022-02-23

Vicore takes major step towards a clinical platform company targeting AT2R – new molecule ready for phase 1

2022-02-10 | Regulatory

Vicore’s AIR study interim analysis suggests that C21 improves lung function in IPF patients

2021-11-04 | Regulatory

Interim report July – September 2021

2021-11-02 | Regulatory

Vicore’s C21 reduces long-term lung injury after COVID-19 in the ATTRACT Phase 2 extension study

2021-10-25

Lancet’s EClinicalMedicine publishes phase 2 data on C21 in COVID-19

2021-10-20 | Regulatory

Vicore announces the Nomination Committee for the 2022 Annual General Meeting

2021-09-22

Vicore to host Key Opinion Leader webinar on C21 for the treatment of idiopathic pulmonary fibrosis (IPF)

2021-09-22

Vicore obtains SARS coronavirus patent for C21 in the USA

2021-09-17

Vicore starts dosing of first COVID-19 patients in the global phase 3 trial ATTRACT-3

2021-08-27 | Regulatory

Vicore strengthens its management team

2021-08-26 | Regulatory

Interim report April – June 2021

2021-06-15

Vicore announces participation in investor meetings during June 2021

2021-06-11

Vicore announces FDA acceptance for pivotal phase 3 trial of C21 in COVID-19

2021-05-11 | Regulatory

Bulletin from the Annual General Meeting of Vicore Pharma Holding AB (publ)

2021-05-05 | Regulatory

Interim report January – March 2021

2021-05-04 | Regulatory

Vicore starts collaboration with Alex Therapeutics to develop new digital therapeutic for patients with IPF

2021-04-20

Vicore Pharma to host Key Opinion Leader webinar on C21 for the treatment of COVID-19

2021-04-15 | Regulatory

Vicore Pharma publishes the Annual Report for 2020

2021-04-08 | Regulatory

Notice of annual general meeting of Vicore Pharma Holding AB (publ)

2021-03-31 | Regulatory

Increase of number of shares and votes in Vicore Pharma

2021-03-11

Vicore Pharma’s drug candidate C21 dilates peripheral resistance vessels in fibrotic disease

2021-03-05 | Regulatory

Press release from the extraordinary general meeting of Vicore Pharma Holding AB (publ)

2021-02-26 | Regulatory

Increase of number of shares and votes in Vicore Pharma

2021-02-26 | Regulatory

Year-end report 2020

2021-02-10 | Regulatory

Notice of extraordinary general meeting of Vicore Pharma Holding AB (publ)

2021-02-10 | Regulatory

Vicore Pharma has completed a directed share issue of SEK 336 million

2021-02-09 | Regulatory

Vicore Pharma intends to carry out a directed share issue

2021-02-01

Positive data from Phase II study ATTRACT in patients with COVID-19 published online

2020-12-21

Positive results show that C21 can become an important complement to COVID-19 vaccines

2020-12-15

Vicore Pharma announces Last Patient Last Visit in the mechanistic phase II study with C21 in systemic sclerosis

2020-12-08 | Regulatory

Vicore Pharma reports positive top line data from the ATTRACT clinical study in patients with COVID-19

2020-11-16

Vicore Pharma recruits the first patient in the phase II Proof-of-Concept study in idiopathic pulmonary fibrosis

2020-11-06 | Regulatory

Interim report July-September 2020

2020-11-03

Vicore announces changes in management team

2020-11-02

Vicore strengthens its pipeline with the acquisition of novel AT2R agonists and decides on an issue in kind of 142,054 shares

2020-10-06 | Regulatory

Vicore Pharma announces the Nomination Committee for the 2021 Annual General Meeting

2020-10-01

Vicore Pharma announces completion of patient enrollment in the COVID-19 ATTRACT trial

2020-09-25

Robust effects of VP01 in human idiopathic pulmonary fibrosis lung tissue

2020-08-31 | Regulatory

Increase of number of shares and votes in Vicore Pharma

2020-08-26 | Regulatory

Interim report April-June 2020

2020-08-25

Vicore Pharma restarts mechanistic study with VP01 in systemic sclerosis

2020-08-13 | Regulatory

Vicore Pharma publishes a prospectus for admission to trading of shares on Nasdaq Stockholm in connection with a directed share issue

2020-07-27

Vicore Pharma doses first COVID-19 patient in the ATTRACT study in India

2020-07-03 | Regulatory

Vicore Pharma has completed a directed share issue of SEK 185 million

2020-07-02 | Regulatory

Vicore Pharma intends to carry out a directed share issue

2020-06-23

Vicore Pharma expands recruitment base for the ATTRACT study

2020-06-22

Vicore Pharma’s drug candidate VP01 demonstrates potential for significant benefit in severe pulmonary hypertension

2020-05-29

LifeArc awards £ 1.5 million grant to Vicore Pharma for the VP01 COVID-19 clinical study

2020-05-20 | Regulatory

Bulletin from the Annual General Meeting of Vicore Pharma Holding AB (publ)

2020-05-05 | Regulatory

Interim report January – March 2020

2020-05-05

Vicore Pharma receives regulatory approval to start phase II clinical trial with VP01 (C21) in patients with IPF

2020-05-04

Vicore offers advance voting in connection with the 2020 AGM

2020-04-28

Vicore Pharma gets regulatory approval to start phase II clinical trial with VP01 (C21) in patients with COVID-19, SARS CoV-2 infection

2020-04-17 | Regulatory

Notice of annual general meeting of Vicore Pharma Holding AB (publ)

2020-04-15 | Regulatory

Vicore Pharma publishes the Annual Report for 2019

2020-03-31 | Regulatory

Vicore Pharma submits Letter of Intent for a clinical trial application for a phase II study in patients with COVID-19, SARS CoV-2 infection

2020-03-30

Vicore submits clinical trial application for phase II trial with C21 in IPF

2020-03-20

Vicore informs on clinical programs in relation to the current outbreak of COVID-19

2020-02-28 | Regulatory

Year-end report 2019

2020-01-31 | Regulatory

Increase of number of shares and votes in Vicore Pharma

2019-12-18

Update on progress for drug development programs VP01 (C21) and VP02 (IMiD)

2019-11-29 | Regulatory

Increase of number of shares and votes in Vicore Pharma

2019-11-13 | Regulatory

Vicore Pharma has completed a directed share issue of approximately SEK 125 million

2019-11-12 | Regulatory

Vicore Pharma intends to carry out a directed share issue

2019-11-08 | Regulatory

Interim report January-September 2019

2019-10-03 | Regulatory

Vicore Pharma announces the Nomination Committee for the 2020 Annual General Meeting

2019-10-01

Update on progress in clinical lead program VP01 (C21)

2019-09-16 | Regulatory

Vicore Pharma publishes prospectus in connection with its listing on Nasdaq Stockholm

2019-09-11 | Regulatory

Vicore Pharma has been approved for listing on Nasdaq Stockholm

2019-09-06 | Regulatory

Safe and well tolerated dose of C21 established in successful dose escalation phase 1 study

2019-08-23 | Regulatory

Interim report April-June 2019

2019-05-15 | Regulatory

Bulletin from the annual general meeting of Vicore Pharma Holding AB (publ)

2019-05-15 | Regulatory

Interim report January – March 2019

2019-04-23 | Regulatory

Vicore Pharma announces systemic sclerosis as the second indication for VP01

2019-04-12 | Regulatory

Notice of Annual General Meeting of Vicore Pharma Holding AB (publ)

2019-04-12 | Regulatory

Vicore Pharma’s Annual Report 2018 published

2019-03-15 | Regulatory

Year-end report 2018

2019-02-13 | Regulatory

Vicore Pharma postpones publication of year-end report

2019-01-07 | Regulatory

Press release from the extraordinary general meeting of Vicore Pharma

2018-11-30 | Regulatory

Notice of extraordinary general meeting of Vicore Pharma Holding AB (publ)

2018-11-30 | Regulatory

Vicore Pharma’s Board of Directors has resolved on a directed share issue of around SEK 160 million to finance the continued development of the drug development programs VP01 and VP02

2018-11-08 | Regulatory

Interim report July-September 2018

2018-11-01 | Regulatory

Vicore Pharma’s rights issue registered – conversion of BTA to shares

2018-10-22 | Regulatory

Göran Wessman resigns from the Board – joins the Nomination Committee now appointed in Vicore Pharma Holding

2018-10-09 | Regulatory

Rights issue in Vicore oversubscribed by 33 percent – The company receives SEK 82.4M

2018-09-26 | Regulatory

Vicore Pharma postpones publication of interim report

2018-09-18 | Regulatory

Vicore publishes prospectus and new financial information contained in the prospectus

2018-09-17 | Regulatory

Vicore Pharma strengthens team with two key hires to support focus on rare lung disease

2018-09-12 | Regulatory

Information relating to the decided rights issue in Vicore Pharma

2018-09-10 | Regulatory

Vicore Pharma expands VP01 (C21) clinical program to enable functional read out

2018-08-30 | Regulatory

Carl-Johan Dalsgaard Appointed New CEO of Vicore Pharma

2018-08-24 | Regulatory

Interim report April-June 2018

2018-08-20 | Regulatory

Vicore Pharmas acquisition of INIM Pharma completed

2018-08-15 | Regulatory

Last day of trading including right to dividend shares in I-Tech AB

2018-08-13 | Regulatory

Press release from the Extra General Meeting August 13, 2018

2018-07-14 | Regulatory

Notice of Extraordinary General Meeting of Vicore Pharma Holding AB (publ)

2018-07-03 | Regulatory

Vicore Pharma and HealthCap create a leading drug development company focused on severe lung diseases

2018-06-13 | Regulatory

Press release from the Annual General Meeting June 13, 2018

2018-05-11 | Regulatory

Summons to attend the Annual General Meeting of Vicore Pharma Holding AB (publ).

2018-05-08 | Regulatory

Interim report January-March 2018

2018-05-07 | Regulatory

Vicore Pharma cancels the AGM on May 8, 2018

2018-04-18 | Regulatory

Vicore Pharma receives approval to start Phase IIa study in IPF

2018-04-12 | Regulatory

Vicore Pharma publish annual report for 2017

2018-04-06 | Regulatory

Summons to attend the Annual General Meeting of Vicore Pharma Holding AB (publ)

2018-03-21

Frontiers in Physiology publish data with C21 on pulmonary fibrosis

2018-03-19

Vicore Pharma’s holding I-Tech enters long-term commercial agreement with global marine paint company

2018-03-13 | Regulatory

Vicore Pharma’s holding I-Tech strengthens supply chain with strategic acquisition

2018-02-21 | Regulatory

Year-end report 2017

2018-02-08 | Regulatory

Vicore Pharma acquires shares in I-Tech

2018-01-26

Highlights from new publications on C21 and the AT2 receptor

2017-12-22 | Regulatory

Vicore Pharma increases its holding in I-Tech AB

2017-12-22 | Regulatory

Vicore Pharma has submitted an application to start a phase II study for Idiopathic Pulmonary Fibrosis

2017-11-08 | Regulatory

Vicore Pharma´s board member Göran Arvidson has passed away

2017-11-01

Vicore Pharma to Attend Two Investor Conferences in London in November 2017

2017-10-19 | Regulatory

Interim report July-September 2017

2017-10-09

Clinical potential of C21 highlighted in review publications

2017-10-02 | Regulatory

Phase I extension study demonstrates beneficial effects on lipid metabolism with C21

2017-08-24 | Regulatory

Interim report April-June 2017

2017-08-17 | Regulatory

Results from extension study with C21 show safety, tolerability and indicate effects on lipid metabolism

2017-06-01 | Regulatory

Vicore Pharma makes strategic recruitments

2017-05-24 | Regulatory

Vicore Pharma appoints Erik Penser Bank as Certified Adviser

2017-05-17 | Regulatory

Newly appointed Chairman of the Board increases his holdings in Vicore Pharma Holding

2017-05-17

Vicore Pharma to participate in Jefferies Healthcare Conference

2017-05-10 | Regulatory

Press release from the Annual General Meeting May 10, 2017

2017-05-10 | Regulatory

Interim report January-March 2017

2017-05-03

New positive study results on diabetic nephropathy with Vicore Pharma’s candidate drug C21

2017-04-10

Interview with Per Jansson, CEO of Vicore Pharma

2017-04-06 | Regulatory

Vicore Pharma Holding publish annual report for 2016

2017-04-03 | Regulatory

Notice of Annual General Meeting in Vicore Pharma Holding AB (publ)

2017-03-27 | Regulatory

Bulletin from the Extraordinary General Meeting on March 27, 2017

2017-03-08 | Regulatory

C21 has a strong impact on several markers in an in vitro study for pulmonary fibrosis

2017-02-23 | Regulatory

Vicore Pharma resolves on directed share issues and publish notice for an extraordinary shareholders’ meeting

2017-02-15

Vicore Pharma extends research portfolio with new drug molecules

2017-01-27 | Regulatory

Vicore Pharma is granted orphan drug designation from FDA for the treatment of IPF

2016-11-09

Phase I-study succesfully completed

2016-09-27

C21 may protect the heart from chemotherapy toxicity

2016-08-01

Vicore Pharma is granted orphan drug designation for C21 for the treatment of IPF

2016-06-30

New research data with C21 on diabetes

2016-06-13

Successful conclusion of the first Phase I study with C21

2016-04-15

Selektope wins European Marine Engineering award

2015-11-05

I-Tech seals market acceptance for Selektope

2015-07-14

Selektope voted for European Union approval

2015-06-10

NEW CHIEF OPERATIONS OFFICER (COO) TO I-TECH

2014-09-12

I-TECH’S SELEKTOPE® APPROVED IN CHINA

2014-07-08

I-Tech signs supply agreement with Chugoku marine paints Ltd

2014-04-09

I-Tech´s Selektope® recommended for EU approval by the UK Health and Safety Executive (HSE)

2012-12-20

Vicore Pharma receives funding for development of angiotensin AT2-receptor agonists for potential treatment of multiple sclerosis